In Phase C, contributors will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will get ABBV-744 and ruxolitinib. Members will get treatment till condition progression or perhaps the individuals are not able to tolerate the study drugs. - "Our study exposed the very important role with the KLF16/MYC regulatory https://johnnyh554teo6.wikifordummies.com/user